



Centrose to Present at the 2016 World Precision Medicine Congress in Washington DC

Brief: Centrose was invited to present at the World Precision Medicine Congress 2016

MADISON, WI USA, November 07, 2016 – Centrose today announced that it will join medical experts at the 2016 World Precision Medicine Congress and present its EDC Technology and precision therapeutics. The conference is being held in Washington DC on November 14th and 15th at the Hyatt Regency Capitol Hill.

World Precision Medicine Congress 2016 will bring together big pharma, big data, and healthcare providers to discuss the scientific, economic, and policy goals towards producing precise and genomic-based medicines. With the launch of President Obama's Precision Medicine Initiative (PMI) this year, this is a market segment that is primed for growth similar to what was seen in the Orphan Drug marketplace. The entire healthcare industry is beginning to shift towards medicines tailored to an individual's genetic make-up, spurred on by better diagnostics and gene sequencing technologies. Biotech is now beginning to bring precision medicines to the clinic that capitalizes on a better understanding of how best treat patients in a safe and effective manner.

"At Centrose we developed the most precise method of directing powerful anti-cancer drugs to sites on cancer cells that do not exist on normal cells" comments Dr. James Prudent, CEO of Centrose, "By using a combination of antibodies and drugs, we have been able to show that EDCs are not only safe, but kill cancer in an entirely new way".

Professor Jon Thorson will present data on Centrose's most advanced drug lead, EDC9. EDC9 combines rituximab with a cardiac glycoside to selectively kill hard to treat non-Hodgkin's Lymphomas. The key to EDC9's success has been that it allows rituximab an additional cell killing mechanism. EDC9 kills rituximab resistant non-Hodgkin's Lymphomas in a completely new and selective manner, something doctors have been looking for.

About Centrose

Centrose is a biopharmaceutical company committed to the discovery and development of safe and effective FDA approved therapies for hard to treat cancers. Centrose identified precision therapeutics called EDCs that have been shown to stop tumor growth while reducing inflammation and activating the body's own defense mechanisms; all leading to safe and effective treatments for cancer patients.

Contacts:

James Prudent
Chief Executive Officer
Centrose 1-608-836-0207
www.centrosepharma.com